News

Spinraza (nusinersen), an approved therapy for people with spinal muscular atrophy (SMA), corrected the splicing defects of the SMN2 gene as designed, but it also brought the two ends of the SMN2 gene into closer physical contact, like a loop, further boosting the gene’s activity. The looping effect…

In a new study using mice, onasemnogene abeparvovec, sold as Zolgensma and Itvisma — two approved gene therapies for spinal muscular atrophy (SMA) — did not cause notable issues in reproductive cells, fertility, or embryonic development. Indeed, the preclinical study found no evidence of reproductive harm due…

Epidural spinal cord stimulation (SCS) may improve walking in people with spinal muscular atrophy (SMA) through better hip mobility and movement without worsening compensatory gait patterns, a small study suggests. The findings build on previous research showing the procedure improved walking distance, muscle strength, and endurance in adults with…

The recent Muscular Dystrophy Association (MDA) Engage Community Seminar with Stanford Medicine was packed with educational sessions, but some of the most meaningful takeaways for participants were about connection and community. “That’s what makes MDA Engage Symposium so special,” Marissa Lozano, director of community education at the MDA,…

The U.S. Food and Drug Administration (FDA) has shared new details concerning reports of cancer developing following treatment with gene therapy for spinal muscular atrophy (SMA). Last week, Novartis confirmed that there have been nine cases of tumors developing after treatment with its gene therapy…

Combining two approaches to address problems in astrocytes, cells that support nerve cells (neurons), may improve communication between motor neurons in spinal muscular atrophy (SMA), a new study suggests. Researchers increased levels of SMN, the protein deficient in SMA, in lab-grown astrocytes derived from patients. They also used forskolin,…

Novartis has confirmed that there have been at least two reports of tumors that appear to have been caused by treatment with Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy that is widely approved for infants and young children with spinal muscular atrophy (SMA). Details about these cases…

Long-term treatment with Spinraza (nusinersen) was associated with early improvements in motor function followed by long-term stability in people with spinal muscular atrophy (SMA) types 2 and 3, according to a real-world study in Turkey. After an average follow-up of more than four years, 75% of patients with…

Canada’s Drug Agency (CDA) recommends expanding public funding for Biogen’s Spinraza (nusinersen) to include adults and more patients with spinal muscular atrophy (SMA). Provincial governments have yet to decide on funding. Still in draft form, the recommendation is to include adults with SMA type 2 or…

Two interconnected themes — community and hope — dominated the conversations at a recent gathering of people living with neuromuscular diseases. Lily Sander, MDA National Ambassador, speaking at MDA Engage: Dallas. (Photo by Tara Haelle) Lily Sander, national ambassador for the Muscular Dystrophy Association (MDA), hit on those…